RxDoctor Payments DataLook up a doctor →

Aravinda Nanjundappa, MD

Interventional Cardiology · Beckley, WVNPI 1447244488

Payments from drug & device makers

$869,175in general payments, 2019–2025

Across 791 payments — averaging $1098.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$236K
  • Shockwave Medical, Inc$117K
  • Abbott$97K
  • Inari Medical, Inc.$83K
  • Cardiovascular Systems Inc.$81K
  • Edwards Lifesciences$73K
  • plus $182K from 35 others
$1,500in research payments, 2019–2025

Across 3 payments — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$2K

What the payments were for

  • Consulting fees$52,64332%
  • Speaking & faculty fees$59,00336%
  • Travel & lodging$36,49522%
  • Food & beverage$17,67911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$869,175 in reported general payments places this provider in the 95th percentile of 46 interventional cardiology providers in West Virginia.

See all interventional cardiology providers in West Virginia

Medicare billing

Part B allowed, 2024
$77,233
Medicare patients
242
Services billed
558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin45$63,406
EntrestoSacubitril/Valsartan32$36,863
XareltoRivaroxaban15$16,945
EliquisApixaban11$13,091
BrilintaTicagrelor22$12,415
Cilostazol93$3,104
Rosuvastatin Calcium124$1,609
Atorvastatin Calcium132$1,268
Ezetimibe28$656
ClopidogrelClopidogrel Bisulfate86$639
Bupropion Hcl SrBupropion Hcl20$573
Metoprolol Succinate49$480
Isosorbide Mononitrate ErIsosorbide Mononitrate36$382
Valsartan13$374
Losartan Potassium47$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$36,86332 claims
PfizerEliquis$2,748$13,09111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 46 interventional cardiology providers in West Virginia.

Other interventional cardiology in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →